Oncotelic Therapeutics, Inc. (OTCQB: OTLC), in collaboration with Sapu Nano, has announced that the first patient has been dosed in a Phase 1b clinical trial evaluating Sapu003, an investigational intravenous Deciparticle formulation of everolimus. The trial targets patients with advanced mTOR-sensitive solid tumors, including HR-positive/HER2-negative breast cancer and other tumor types.
The open-label, dose-escalation study is designed to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Sapu003 is a weekly intravenous formulation intended to overcome limitations associated with oral everolimus delivery, such as variable absorption and dose-limiting toxicity. This advancement could represent a significant improvement in the therapeutic landscape for patients with mTOR-sensitive cancers, offering a more consistent and potentially safer dosing regimen.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company leverages a robust portfolio of inventions from its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic utilizes its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes through advanced data analysis.
Beyond its internal programs, Oncotelic licenses and co-develops drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates in oncology and rare disease therapeutics.
The initiation of this Phase 1b trial marks a critical step in the clinical development of Sapu003. If successful, the treatment could offer a new option for patients with advanced solid tumors that have limited therapeutic choices. For investors and industry watchers, this development underscores Oncotelic's commitment to innovative drug delivery technologies and its focus on addressing significant unmet medical needs.
For more information on Oncotelic Therapeutics, visit the company's newsroom at https://ibn.fm/OTLC. The full press release is available at https://ibn.fm/JuGIs.
